
MediWound (MDWD) Stock Forecast & Price Target
MediWound (MDWD) Analyst Ratings
Bulls say
MediWound Ltd is positioned favorably due to its innovative biopharmaceutical products, including the FDA-approved NexoBrid, which addresses significant unmet medical needs in the treatment of severe burns and chronic wounds. The company's revenue stream is primarily generated from the United States, with additional contributions from the European Union and other international markets, highlighting its potential for growth in diverse regions. Although the recent financial results for 1Q24 showed total revenues of $4.0 million, slightly below consensus estimates, MediWound's ongoing developments and product pipeline remain key indicators of long-term financial viability and growth potential.
Bears say
MediWound Ltd has postponed the U.S. launch of its product EscharEx by one year, now scheduled for the third quarter of 2028, which indicates potential delays in revenue generation and market penetration. The continuous indication of no income or loss from discontinued operations suggests a lack of significant financial activities that could bolster earnings or offset losses. Such factors contribute to a negative outlook on the company's stock, reflecting concerns regarding growth timelines and overall financial performance.
This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.
MediWound (MDWD) Analyst Forecast & Price Prediction
Start investing in MediWound (MDWD)
Order type
Buy in
Order amount
Est. shares
0 shares